Use of adjuvant chemotherapy for early-stage low-grade serous ovarian carcinoma

2020 ◽  
Vol 159 ◽  
pp. 61
Author(s):  
J.K. Oh ◽  
D. Nasioudis ◽  
S. Gysler ◽  
E.M. Ko ◽  
M.A. Morgan ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Early Stage ◽  
Low Grade ◽  
Serous Ovarian Carcinoma

scholarly journals Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma

2019 ◽  
Author(s):  
Elien De Thaye ◽  
Koen Van de Vijver ◽  
Joni Van der Meulen ◽  
Joachim Taminau ◽  
Glenn Wagemans ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Cell Line ◽  
Peritoneal Metastasis ◽  
Early Stage ◽  
Estrogen Signaling ◽  
Low Grade ◽  
Patient Derived Xenograft ◽  
Serous Ovarian Carcinoma ◽  
Pdx Model

AbstractPeritoneal spread indicates poor prognosis in patients with serous ovarian carcinoma (SOC) and is generally treated by surgical cytoreduction and chemotherapy. Novel treatment options are urgently needed to improve patient outcome. Clinically relevant cell lines and patient-derived xenograft (PDX) models are of critical importance to therapeutic regimen evaluation. Here, a PDX model was established by orthotopic engraftment, subperitoneal tumor slurry injection, of low-grade SOC resulting in an early-stage transplantable peritoneal metastasis (PM)-PDX model. Histology confirmed the micropapillary and cribriform growth pattern with intraluminal tumor budding and positivity for PAX8 and WT1. PM-PDX dissociated cells show an epithelial morphotype with a 42h doubling time and 40% colony forming efficiency, they are insensitive to estrogen signaling, low sensitive to platinum derivatives and highly sensitive to paclitaxel (IC50: 6.3 ± 2.2 nM, mean ± SE). The patient primary tumor, PM, PM-PDX and derived cell line all show a KRAS c.35G>T (p.(Gly12Val)) mutation and show sensitivity to the MEK inhibitor trametinib in vitro (IC50: 7.2 ± 0.5 nM, mean ± SE) and in the PM mouse model. These preclinical models closely reflecting patient tumors are useful to further elucidate LGSOC disease progression, therapy response and resistance mechanisms.

scholarly journals Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jun-Hyeok Kang ◽  
Yen-Ling Lai ◽  
Wen-Fang Cheng ◽  
Hyun-Soo Kim ◽  
Kuan-Ting Kuo ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Advanced Disease ◽  
Residual Disease ◽  
Figo Stage ◽  
Low Grade ◽  
High Grade ◽  
Serous Ovarian Carcinoma ◽  
Number Of Cycles

AbstractLow-grade ovarian serous carcinoma (LGSOC) has clinical features different from high-grade serous ovarian carcinoma (HGSOC) accounting for the majority of epithelial ovarian cancer. Because of its rarity, previous studies have only focused on the high-grade disease without considering the differences between the two subtypes. This study aimed to evaluate the effect of the clinical prognostic factors known for HGSOC on survival in patients with LGSOC. Based on the Federation of Gynecology and Obstetrics (FIGO) stage, progression-free survival (PFS) was markedly decreased in advanced disease compared with early disease. For stage I, patients with stage IC had poorer survival than those with stage IA and IB regardless of the number of cycles of adjuvant chemotherapy. For advanced disease, no gross residual disease after primary cytoreductive surgery was significantly associated with longer PFS when compared with gross residual disease. In multivariate analysis for PFS and overall survival (OS), age, preoperative CA-125, time interval from surgery to chemotherapy, and the number of cycles of adjuvant chemotherapy were not associated with prognosis. Complete cytoreduction was the only independent prognostic factor for PFS (HR 2.45, p = 0.045). Our study revealed that the known prognostic factors in HGSOC did not show any effect on the survival in LGSOC except for FIGO stage and complete cytoreduction.

scholarly journals Trends of low-grade serous ovarian carcinoma in the United States

2018 ◽  
Vol 29 (1) ◽  
Author(s):  
Koji Matsuo ◽  
Hiroko Machida ◽  
Brendan H. Grubbs ◽  
Anil K. Sood ◽  
David M. Gershenson
Keyword(s):  
United States ◽  
Ovarian Carcinoma ◽  
The United States ◽  
Low Grade ◽  
Serous Ovarian Carcinoma

scholarly journals Low-grade Serous Ovarian Carcinoma

2018 ◽  
Vol 78 (10) ◽  
pp. 972-976 ◽  
Author(s):  
Enzo Ricciardi ◽  
Thaïs Baert ◽  
Beyhan Ataseven ◽  
Florian Heitz ◽  
Sonia Prader ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Ovarian Carcinoma ◽  
Systemic Treatment ◽  
Hormonal Treatment ◽  
Current Treatment ◽  
Low Grade ◽  
Separate Entity ◽  
Serous Ovarian Carcinoma ◽  
Number Of Patients

AbstractIn the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.

scholarly journals Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1336
Author(s):  
Angiolo Gadducci ◽  
Stefania Cosio
Keyword(s):  
Ovarian Carcinoma ◽  
Endocrine Therapy ◽  
Biological Behavior ◽  
Lower Sensitivity ◽  
Low Grade ◽  
Targeted Agents ◽  
Mek Inhibitors ◽  
Serous Ovarian Carcinoma ◽  
Fertility Sparing ◽  
Molecularly Targeted Agents

Low-grade serous ovarian carcinoma (LGSOC) is a distinct pathologic and clinical entity, characterized by less aggressive biological behavior, lower sensitivity to chemotherapy and longer survival compared with high-grade serous ovarian carcinoma. LGSOC often harbors activating mutations of genes involved in mitogen activated protein kinase (MAPK) pathway. Patients with disease confined to the gonad(s) should undergo bilateral salpingo-oophorectomy, total hysterectomy and comprehensive surgical staging, although fertility-sparing surgery can be considered in selected cases. Women with stage IA-IB disease should undergo observation alone after surgery, whereas observation, chemotherapy or endocrine therapy are all possible options for those with stage IC-IIA disease. Patients with advanced disease should undergo primary debulking surgery with the aim of removing all macroscopically detectable disease, whereas neoadjuvant chemotherapy followed by interval debuking surgery. After surgery, the patients can receive either carboplatin plus paclitaxel followed by endocrine therapy or endocrine therapy alone. Molecularly targeted agents, and especially MEK inhibitors and Cyclin-dependent kinase (CDK) inhibitors, are currently under evaluation. Additional research on the genomics of LGSOC and clinical trials on the combination of MEK inhibitors with hormonal agents, other molecularly targeted agents or metformin, are strongly warranted to improve the prognosis of patients with this malignancy.

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy

2019 ◽  
Vol 30 (10) ◽  
pp. 1619-1626 ◽  
Author(s):  
Ioannis A Voutsadakis
Keyword(s):  
Clinical Trials ◽  
Targeted Therapy ◽  
Ovarian Carcinoma ◽  
Molecular Profile ◽  
Low Grade ◽  
High Grade ◽  
Novel Therapies ◽  
Precursor Lesions ◽  
Molecular Defects ◽  
Serous Ovarian Carcinoma

Low-grade serous ovarian carcinoma and its high-grade serous ovarian carcinoma counterpart differ in their precursor lesions, molecular profile, natural history, and response to therapies. As such, low-grade serous ovarian carcinoma needs to be studied separately from high-grade serous ovarian carcinoma, despite challenges stemming from its rarity. A deeper understanding of the pathogenesis of low-grade serous ovarian carcinoma and the most common molecular defects and pathways involved in the carcinogenesis of the ovarian epithelium from normal to serous borderline ovarian tumors to low-grade serous ovarian carcinoma will help develop better therapies. By adopting targeted approaches there may be an opportunity to integrate novel therapies without the need for robust numbers in clinical trials. This manuscript will discuss low-grade serous ovarian carcinoma and focus on the arising treatments being developed with an improved understanding of the pathogenesis of this disease.

Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma

2019 ◽  
Vol 154 (2) ◽  
pp. 302-307 ◽  
Author(s):  
Dimitrios Nasioudis ◽  
Ashley F. Haggerty ◽  
Robert L. Giuntoli ◽  
Robert A. Burger ◽  
Mark A. Morgan ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Survival Benefit ◽  
Early Stage ◽  
Mucinous Ovarian Carcinoma

scholarly journals Ultrasound, macroscopic and histological features of serous epithelial ovarian carcinomas

2020 ◽  
pp. ijgc-2020-001473
Author(s):  
Paola Romeo ◽  
Damiano Arciuolo ◽  
Maria Cristina Moruzzi ◽  
Francesca Moro
Keyword(s):  
Ovarian Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Ovarian Carcinomas ◽  
Histological Features ◽  
Serous Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinomas

We present a video showing two cases of serous epithelial ovarian carcinomas. The first video shows clinical, ultrasound, macroscopic, and histological features of a patient with high grade serous ovarian carcinoma. The second video presents clinical, ultrasound, macroscopic, and histological features of a patient with low grade serous ovarian carcinoma.

Sign in / Sign up

Export Citation Format

Share Document